Protagonist Therapeutics, Inc. (PTGX) Stock: Here’s Why It’s Down


Protagonist Therapeutics, Inc. (PTGX) is headed down in the market in today’s trading session. The stock, one that is focused on the biotech space, is currently trading at $12.31 after heading down -5.02% so far in today’s session. When it comes to biotechnology companies, there are quite a few factors that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines associated with PTGX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-01-19 07:00AM Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
Mar-18-19 11:12AM Edited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMT
Mar-12-19 04:25PM Protagonist Therapeutics: 4Q Earnings Snapshot
04:01PM Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Mar-05-19 07:00AM Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look into much more than news, especially in the highly speculative biotech sector. Here’s what’s going on with Protagonist Therapeutics, Inc..

Trends That We’ve Seen From PTGX

Although a single session decline, like the move that we’re seeing from Protagonist Therapeutics, Inc. might make some investors tremble, a single session move by itself should not be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to take a look at trends experienced by the stock beyond a single session. As it relates to PTGX, here are the returns on investment that we’ve seen:

  • Past 5 Trading Sessions – Over the last week, PTGX has generated a change in price in the amount of -2.84%.
  • Past 30 Days – The ROI from Protagonist Therapeutics, Inc. throughout the last 30 days works out to 34.83%.
  • Past 3 Months – In the last 3 months, the stock has produced a return on investment that comes to 71.93%
  • Past Six Months – In the previous six months, we have seen a performance of 30.54% from the stock.
  • Year To Date – Since the close of last year PTGX has generated a ROI of 82.91%.
  • Annually – Finally, over the last full year, we’ve seen movement that works out to 40.21% out of PTGX. In this period, the stock has sold at a high price of -14.28% and a low of 124.12%.

Notable Ratios

Looking at various ratios having to do with a company generally gives traders an understanding of how risky and/or rewarding a stock pick might be. Below are a few of the most important ratios to think about when looking at PTGX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it shows that more investors are expecting that the value of the stock is going to go down. Throughout the sector, biotech stocks tend to come with a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, with regard to Protagonist Therapeutics, Inc., the stock’s short ratio is 2.48.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. In the biotechnology sector, companies are heavily reliant on continued investor support, the quick and current ratios can be upsetting. However, several good picks in the biotechnology space come with great current and quick ratios. When it comes to PTGX, the quick and current ratios come to 5.30 and 5.30 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. In this case, the book to share value ratio works out to 4.65.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value comes to 5.53.

What Analysts Think About Protagonist Therapeutics, Inc.

While it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their thoughts when validating your own when it comes to making investment decisions in the biotechnology space. Here are the recent moves that we’ve seen from analysts as it relates to PTGX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-06-18 Initiated Nomura Buy $13
Jan-29-18 Initiated Stifel Buy $32
Jul-21-17 Initiated BTIG Research Buy $36

Is Big Money Interested In Protagonist Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PTGX, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors hold 90.20% of Protagonist Therapeutics, Inc.. Nonetheless, it is worth noting that institutional ownership has seen a move in the amount of 0.00% throughout the last quarter.
  • Insider Moves – When it comes to insiders, those close to the situation currently hold 2.10% of the company. Their ownership of the company has moved -4.14% over the past 3 months.

What You Need To Know About Share Counts

Traders and investors seem to have an interest in the total numbers of shares both available and outstanding. As it relates to Protagonist Therapeutics, Inc., there are currently 23.31M with a float of 22.15M. These numbers mean that of the total of 23.31M shares of PTGX currently in existence today, 22.15M are able to be traded by the public.

I also like to take a look at the short percent. After all, when a high portion of the float available for trading is shorted, the overall opinion among traders is that the stock is going to fall. In regard to PTGX, the percentage of the float that is shorted currently sits at 1.95%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. However, I’ve calculated that a short ratio over 26% is usually a risky play.

What We’ve Seen In Financial Results

What have ween seen from PTGX in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, analysts expect that PTGX will come up with earnings per diluted share of -2.71, with -0.66 to be reported in the earnings report for the current quarter. Although this is not tide to earnings, because we are chatting about analysts, Protagonist Therapeutics, Inc. is presently rated a 1.80 considering a scale that ranges from 1 to 5 on which 1 is the worst possible analyst grade and 5 is the best.
  • 5-Year Sales – In the past half decade, Protagonist Therapeutics, Inc. has generated a change in sales that adds up to 0. Earnings per share through the past 5 years have generated movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly explained in today’s society, Protagonist Therapeutics, Inc. has seen a earnings change by -279.50%. The company has also seen movement when it comes to sales volume that totals -78.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I’m highly dependent on human beings. A human built me! Although, my builder enabled me to learn on my own, it is a lot easier to do so through the receipt of human feedback. At the bottom of this article, you will find a section for comments. If you would like for me find other information, evolve the way I write something, comprehend information from a different angle, or just about anything else, I’d like to know. If you’ve got something to offer leave a comment below. I’ll process that lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here